Deferasirox,
an FDA-approved iron chelator, has gained increasing
attention for use in anticancer and antimicrobial applications. Recent
efforts by our group led to the identification of this core as an
easy-to-visualize aggregation-induced emission platform, or AIEgen,
that provides a therapeutic effect equivalent to deferasirox (J. Am. Chem. Soc.
2021, 143, 3, 1278–1283). However, the emission wavelength of the first-generation
system overlapped with that of Syto9, a green emissive dye used to
indicate live cells. Here, we report a library of deferasirox derivatives
with various fluorescence emission profiles designed to overcome this
limitation. We propose referring to systems that show promise as both
therapeutic and optical imaging agents as “illuminoceuticals”.
The color differences between the derivatives were observable to the
unaided eye (solid- and solution-state) and were in accord with the
Commission Internationale de L’Eclairage (CIE) chromaticity
diagram 1913. Each fluorescent derivative successfully imaged the
respective spherical and rod shapes of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas
aeruginosa. They also displayed iron-dependent antibiotic
activity. Three derivatives, ExNMe
2
(3), ExTrisT (11),
and ExDCM (13), display emission features
that are sufficiently distinct so as to permit the multiplex (triplex)
imaging of both MRSA and P. aeruginosa
via stimulated emission depletion microscopy. The
present deferasirox derivatives allowed for the construction of a
multi-fluorophore sensor array. This array enabled the successful
discrimination between Gram-positive/Gram-negative and drug-sensitive/drug-resistant
bacteria. Antibiotic sensitivity and drug-resistant mutants from clinically
isolated strains could also be identified and differentiated.